These approaches include striking most-favored nation deals with GLP-1 manufacturers Novo Nordisk and Eli Lilly, providing access to discounted prices for GLP-1s through TrumpRx, and proposing to implement a new demonstration program called the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model to expand Medicare and Medicaid coverage of GLPs for obesity, which is currently subject to statutory limitations (prohibited in Medicare, permissible but not required in Medicaid)
Much of the current evidence comes from secondary analyses or small cohort studies
Benjamin, J., Levine, J., Fux, M., Aviv, A., Levy, D., & Belmaker, R
Treasure Island (FL)2025 Baekdal TA, Borregaard J, Hansen CW, Thomsen M, Anderson TW (2019) Effect of oral semaglutide on the pharmacokinetics of lisinopril, warfarin, digoxin, and metformin in healthy subjects
Protein Expression and Signalling Analysis: Evaluating transcriptional and translational changes under controlled experimental conditions
The author evaluated pain intensity, quality, and location using the patients report